Paul Toren1, Lih-Ming Wong2, Narhari Timilshina3, Shabbir Alibhai4, John Trachtenberg3, Neil Fleshner3, Antonio Finelli3. 1. Department of Urologic Sciences, University of British Columbia, Vancouver, BC; 2. Department of Urology, St. Vincent's Hospital and Austin Health, University of Melbourne, Victoria, Australia; 3. Department of Surgery (Urology), University of Toronto, Princess Margaret Hospital, Toronto, ON; 4. Department of Medicine and Institute of Health Policy, Management, and Evaluation, University Health Network and University of Toronto, Toronto, ON.
Abstract
INTRODUCTION: The use of prostate-specific antigen (PSA) in active surveillance (AS) for prostate cancer is controversial. Some consider it an unreliable marker and others as sufficient evidence to exclude patients from AS. We analyzed our cohort of AS patients with a PSA over 10 ng/mL. METHODS: We included patients who had clinical T1c-T2a Gleason ≤6 disease, and ≤3 positive cores with ≤50% core involvement at diagnostic biopsy and ≥2 total biopsies. Patients were divided into 3 groups: (1) those with baseline PSA >10 ng/mL, (2) those with a PSA rise >10 ng/mL during follow-up; and (3) those with a PSA <10 ng/mL throughout AS. Adverse histology was defined as biopsy parameters exceeding the entry criteria limits. We further compared this cohort to a concurrent institutional cohort with equal biopsy parameters treated with immediate radical prostatectomy. RESULTS: Our cohort included 698 patients with a median follow-up of 46.2 months. In total, 82 patients had a baseline PSA >10 ng/mL and 157 had a PSA rise >10 ng/mL during surveillance. No difference in adverse histology incidence was detected between groups (p = 0.3). Patients with a PSA greater than 10 were older and had higher prostate volumes. Hazard ratios for groups with a PSA >10 were protective against adverse histology. Larger prostate volume and minimal core involvement appear as factors related to this successful selection of patients to be treated with AS. CONCLUSION: These results suggest that a strict cut-off PSA value for all AS patients is unwarranted and may result in overtreatment. Though lacking long-term data and validation, AS appears safe in select patients with a PSA >10 ng/mL and low volume Gleason 6 disease.
INTRODUCTION: The use of prostate-specific antigen (PSA) in active surveillance (AS) for prostate cancer is controversial. Some consider it an unreliable marker and others as sufficient evidence to exclude patients from AS. We analyzed our cohort of AS patients with a PSA over 10 ng/mL. METHODS: We included patients who had clinical T1c-T2a Gleason ≤6 disease, and ≤3 positive cores with ≤50% core involvement at diagnostic biopsy and ≥2 total biopsies. Patients were divided into 3 groups: (1) those with baseline PSA >10 ng/mL, (2) those with a PSA rise >10 ng/mL during follow-up; and (3) those with a PSA <10 ng/mL throughout AS. Adverse histology was defined as biopsy parameters exceeding the entry criteria limits. We further compared this cohort to a concurrent institutional cohort with equal biopsy parameters treated with immediate radical prostatectomy. RESULTS: Our cohort included 698 patients with a median follow-up of 46.2 months. In total, 82 patients had a baseline PSA >10 ng/mL and 157 had a PSA rise >10 ng/mL during surveillance. No difference in adverse histology incidence was detected between groups (p = 0.3). Patients with a PSA greater than 10 were older and had higher prostate volumes. Hazard ratios for groups with a PSA >10 were protective against adverse histology. Larger prostate volume and minimal core involvement appear as factors related to this successful selection of patients to be treated with AS. CONCLUSION: These results suggest that a strict cut-off PSA value for all AS patients is unwarranted and may result in overtreatment. Though lacking long-term data and validation, AS appears safe in select patients with a PSA >10 ng/mL and low volume Gleason 6 disease.
Authors: Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler Journal: N Engl J Med Date: 2012-07-19 Impact factor: 91.245
Authors: Katja Fall; Hans Garmo; Ove Andrén; Anna Bill-Axelson; Jan Adolfsson; Hans-Olov Adami; Jan-Erik Johansson; Lars Holmberg Journal: J Natl Cancer Inst Date: 2007-04-04 Impact factor: 13.506
Authors: Ari Adamy; David S Yee; Kazuhito Matsushita; Alexandra Maschino; Angel Cronin; Andrew Vickers; Bertrand Guillonneau; Peter T Scardino; James A Eastham Journal: J Urol Date: 2010-12-17 Impact factor: 7.450
Authors: Antonio Finelli; Greg Trottier; Nathan Lawrentschuk; Robert Sowerby; Alexandre R Zlotta; Lenny Radomski; Narhari Timilshina; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Micheal A S Jewett; John Trachtenberg; Neil E Fleshner Journal: Eur Urol Date: 2010-12-28 Impact factor: 20.096
Authors: Raj Satkunasivam; Girish S Kulkarni; Alexander R Zlotta; Robin Kalnin; John Trachtenberg; Neil E Fleshner; Robert J Hamilton; Michael A S Jewett; Antonio Finelli Journal: J Urol Date: 2013-01-12 Impact factor: 7.450
Authors: Lih-Ming Wong; Shabbir M H Alibhai; Greg Trottier; Narhari Timilshina; Theodorus Van der Kwast; Alexandre Zlotta; Nathan Lawrentschuk; Girish Kulkarni; Robert Hamilton; Sarah Ferrara; David Margel; John Trachtenberg; Michael A Jewett; Ants Toi; Andrew Evans; Neil E Fleshner; Antonio Finelli Journal: Eur Urol Date: 2013-05-02 Impact factor: 20.096
Authors: Michael K Ng; Nicholas Van As; Karen Thomas; Ruth Woode-Amissah; Alan Horwich; Robert Huddart; Vincent Khoo; Alan Thompson; David Dearnaley; Chris Parker Journal: BJU Int Date: 2008-10-16 Impact factor: 5.588
Authors: Ashraf Abusamra; Esam Murshid; Hussain Kushi; Sultan Alkhateeb; Mubarak Al-Mansour; Ahmad Saadeddin; Danny Rabah; Shouki Bazarbashi; Mohammed Alotaibi; Abdullah Alghamdi; Khalid Alghamdi; Abdullah Alsharm; Imran Ahmad Journal: Urol Ann Date: 2016 Apr-Jun
Authors: Ali Aljubran; Ashraf Abusamra; Sultan Alkhateeb; Mohammed Alotaibi; Danny Rabah; Shouki Bazarbashi; Hussain Alkushi; Mubarak Al-Mansour; Hulayel Alharbi; Amin Eltijani; Abdullah Alghamdi; Abdullah Alsharm; Imran Ahmad; Esam Murshid Journal: Urol Ann Date: 2018 Apr-Jun